Life long Maverick: Seen it ALLl in 40 yrs of PROF. exposure as invest analyst/port mgr on the FRONT lines vs iHub Msg Bds.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
martyDg re:
sts66 re Eversept Ptnrs:
https://www.nasdaq.com/quotes/institutional-portfolio/eversept-partners-lp-1045267
https://finance.yahoo.com/amphtml/news/eversept-partners-return-aum-holdings-191420315.html
DIFFERENT STROKES FOR DIFFERENT FOLKS
Sojourner55 re:
Amgen’s Gene-Targeting Drug Shrank 54% of Lung Tumors in Study
CEO Linda Powers husband Bob Hemphill: BOTH with Energizer achievements:
I'm proud to be Canadian! GO CANADA!
NEVER has a first time entrant into Tennis' US Open has one taken THE CROWN:
Bianca Andreescu beats Serena Williams in US Open in straight sets!
Will be posting for a week thru next Monday Sept 15th some of my pictures of OH Canada in recognition of the above.
Today's PROFILE picture was hiking through a NON touristy nor commercial trail (NOT ME)miles away from the Columbia Icefields: sample:
https://www.banffjaspercollection.com/attractions/columbia-icefield/experience/
Tues: hiking away/above Banff Hotel by Lake Louise
Thurs: Canoeing on Lake Louise
Sat: Jasper in Canadian Rockies
DIFFERENT STROKES FOR DIFFERENT FOLKS
By now 99.9% should agree with the RELEVANCE of this RARE 2006 personal interview Linda Powers: Do CONTRAST the Before AND NOW!:
Extremist & Sojourner55 re:
I'm proud to be Canadian! GO CANADA!
Thanks Sharpie: did see thanks to you the UCLA video where Jaimie found out in the last 15 minutes that instead of going to UCSF for his GBM, UCLA’s Dr Linda Liau cut short her Hawaii vacation and performed Jaimie’s successful DCVAX L. Talk about heart and soul dedication of driven Dr. Linda Liau.
SAME should be said of what’s known of our CEO Linda Powers!
Expanded beyond that to the fact Jaimie is both a tennis player and lawyer: reminds me of Mario Ancic from Croatia that beat Roger Federer( early 2000 period) but had to give up playing at that level due to injuries and moved on to get his JD @ Columbia Law School: working as an Wall ST Investment Banker(grueling hrs!). Brings back my mental recall of tennis players/lawyers in the 1970’s Chuck McKinley; Marty Grabner; Donald Dell! etc
DIFFERENT STROKES FOR DIFFERENT FOLKS
EDIT:
Another Thanks to Sharpie which was going to be posted but found I had to attach here:
Re rancher why he whines: swing trader some shades of Pyrrh to shaking holders to sell: for him to add!
Thanks to iwasadiver who BEGAN the simmer to a boil NOW re Dr. Kevin Duffy hire from Merck as an upstream VITAL agent for our NWBO completing this VITAL phase for unlocking the full potential commercialization and value of NWBO's DC VAX PLATFORM.
Fortunately over the last few days most all of the thoughtful movers and shakers after serious thoughts and deliberation have come to the above perspective which I REFRAINED from posting specifically.
From keeping tabs on BMY/Celgene and the sale of Otezia I concluded that the likelihood of BMY being
a seriously interested partner for NWBO has diminished greatly: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150957744
Whereas Merck would seriously want to further catapult Keytruda distance from BMY's recent oncology setbacks. along with many other Big Pharma's:
Why I began the STARS ARE ALIGNED post on Dr. Duffy's STRATEGIC hire emanated from these series of articles I've read and I am posting for your edification IF one wants to do the ongoing COMPLETE DD PROCESS (why do you think there are NOT enough hours in the day to be AHEAD of the CURVE?); Investing takes lots of serious investigative work BEYOND just NWBO:
Perlmutter (MRK's R&D Head) was never big on bold, risky acquisitions. At Amgen, before Ken Frazier brought him back to Merck, Perlmutter was well known for selectively targeting biotechs which he openly admired for their science and leadership. Picking up the pace now may not come naturally for someone like the R&D chief, not much of a wheeler-dealer, but with decades of experience and a global BD team with uncommon reach, it shouldn’t prove impossible.
Peloton’s lead candidate is PT2977, a novel oral HIF-2alpha inhibitor in a Phase II clinical trial for von Hippel-Lindau disease-associated development for renal cell carcinoma (RCC). The company is planning on beginning patient enrollment in a Phase III trial in patients with metastatic clear cell RCC that has been previously treated.
The drug is also being investigated in metastatic RCC in combination with a VEGFR inhibitor, cabozantinib, and in glioblastoma. The company also has]PT2567 in preclinical studies for pulmonary arterial hypertension (PAH)
Just last week, Peloton announced an initial public offering (IPO) with plans to raise $150 million with a market cap of almost $750 million/quote]
I posted early June 2019:
maverick_1 Member Level Monday, 06/10/19 05:42:17 PM
Re: maverick_1 post# 228406
Post # 232605 of 232605
Latest Merck oncology purchase:
Merck is interested in ways of broadening the potential of its checkpoint inhibitor Keytruda (pembrolizumab). Although in many ways a miracle drug, only a small percentage of patients respond to checkpoint inhibitors like Keytruda Anti-TGFB may help with the effectiveness of checkpoint inhibitors
This deal is the third cancer-focused deal Merck has made recently. It acquired Immune Design in February for $300 million and in May bought Peloton Therapeutics for $2.2 billion.
Merck Buys Tilos for Up to $773 Million to Expand Oncology Pipeline
Kenilworth, NJ-based Merck & Co. is buying Lexington, Mass.-based Tilos Therapeutics in a deal that could hit $773 million.
Tilos focuses on developing drugs that target the latency-associated peptide (LAP)-TGF beta complex to treat cancer, fibrosis and autoimmune diseases. TGF beta stands for transforming growth factor beta. The company was founded based on the research of Galina Gabriely and Howard Weiner at the Brigham and Women’s Hospital. Weiner’s work focused on serious autoimmune diseases, which led to LAP and the expression of LAP on suppressive cell populations. The laboratory developed antibodies to LAP, which have an effect on tumor growth.
“At Merck we continue to enhance our robust pipeline through active execution of our business development strategy,” stated Dean Li, Senior Vice President of Discovery and Translational Medicine at Merck Research Laboratories. “Tilos has developed a compelling portfolio of candidates that employ a novel approach to modulating the potent signaling molecule TGF beta by binding to latency-associated peptide, with potential applications across a range of disease indications.”
Under the terms of the deal, a [color=red]Merck subsidiary is buying all outstanding shares of Tilos for a total of up to $773 million, including an upfront payment and various potential milestone payments.
Tilos was founded by Boehringer Ingelheim Venture Fund and Partners Innovation Fund. Additional investment was by ShangPharma Innovation Fund.
TGF beta is secreted with LAP. LAP creates a cage around TGF beta, holding it in an inactive state until it is needed. Research has indicated that anti-LAP antibodies block the release of TGF beta from the TGFB-LAP complex.
“We are proud that the Tilos team has advanced the discoveries of our scientific founders by developing a portfolio of anti-LAP antibodies designed to realize the full potential of TGFB-modulating therapeutics,” stated Barbara Fox, chief executive officer of Tilos. “This agreement with Merck, an industry leader in biopharmaceutical research and development, provides meaningful validation for our therapeutic approach and best positions our pipeline for broad clinical and commercial success.”
TGF beta is produced by a broad spectrum of immune cells. When activated, it can promote cancer by several different mechanisms, including angiogenesis and metastasis and by stimulating the development and differentiation of Tregs (T regulatory cells) and other immunosuppressive cell types. Tilos’ approach is to prevent the activation and release of mature TGF beta.
The primary focus has been in cancer with testing of the anti-TGFB antibodies with checkpoint inhibitors. The antibodies are being investigated in melanoma, glioblastoma and colorectal cancer. Other cancers include renal, hepatocellular, lung, breast and pancreatic cancers. It also has potential for treatments for various autoimmune diseases and fibrosis.
Merck is interested in ways of broadening the potential of its checkpoint inhibitor Keytruda (pembrolizumab). Although in many ways a miracle drug, only a small percentage of patients respond to checkpoint inhibitors like Keytruda. Anti-TGFB may help with the effectiveness of checkpoint inhibitors.
This deal is the third cancer-focused deal Merck has made recently. It acquired Immune Design in February for $300 million and in May bought Peloton Therapeutics for $2.2 billion.
As much as execs hyped up the growth potential across the entire pipeline, Keytruda remains the foundational program as an unprecedented, extremely large product that’s “only going to get bigger” according to Frazier.
“I really believe we’re still in the early stages of the opportunity we have with Keytruda,” added Frank Clyburn, chief commercial officer. And if you take Lynparza and Lenvima into account, “we believe over the next five years I want you to think about the opportunity for more than 50 additional indications.”
Merck slide
Source: Merck
The massive network of trials centered around Keytruda has pushed over the 1,000 mark, Baynes said, with more than 100 in earlier lines of therapy (before or right after surgery), upwards of 600 combinations, and 75 registrational studies underway.
Breast and prostate cancers loom large among them. As monotherapy approaches have proven weak, Merck is looking at new combos and earlier lines for potential first-to-market opportunities. The PARP inhibitor Lynparza might also play a big role in tackling those two markets, while Merck and partner AstraZeneca explore 19 other indications for the drug.
rancher64 re:
Duffy joined to NWBO from Merck means
he was not that important person in Merck (in my strong opinion IMSO)
Simply put re Dr.Kevin Duffy or ANY strategic decision by CEO Linda Powers has been EXEMPLARY IMHO:
Some may recall in 2014-15 many calling for a CFO hire which I castigated logically for the right reasons.
Her Bio which is a MUST READ I posted in mid May is an EYE Opener.
Toucan Partners where CEO Linda Powers and her husband set up was early VISIONARY in Regenerative Medicine etc:
Key example being in ~2005 buying at Bankruptcy Proceeding of GeneSys NEW manufacturing facility
in Memphis, TN: Cognate BioSciences for 15-20cts on the $. Bringing in her clone: husband and wife
team Piri's for legal counseling and CFO grooming it for SALE in MLBO ONLY to keep NWBO ALIVE! courtesy of having her financial playbook in TATERS due to the SNAKEY Neil Woodford
$185 million infusion but with an underhanded hideous agenda under the veil of "a white knight": Fortunately
I bailed OUT late 2015!
THEN in ~2006 funding NWBO then based in Seattle
2012: Becoming NWBO CEO in the throes of the mismanaged Dendreon investment Battle Royale
2014: LUCKILY could NOT come to terms re Leipzig, Germany so
INSTEAD Multitasking within 2 mos Bought Sawston 500 acre plus warts and all that has
provided NWBO the critically needed money; REFINANCED IT TWICE along with BIG COUP late 2018 for Huawei campus:
ALL of these were death defying Wallendia like
:
Marzan re:
NWBO hired Dr. Duffy who oversaw Merck's 20B revenue drug Keytruda this week
Merck’s (NYSE:MRK) Keytruda is its top selling drug with sales of over $7 billion in 2018.
Fri 2 days later Technical read@NOON
Short term trending is POSITIVE and continues to REFUTE FlyFishing Negative Chart read in:
Last few days closing near the highs of each day
Bollinger Bands is at the high end and getting narrower
IMPROVING Relative Strength AND MACD AND Money Flow Index
Coming convergence of 50 DMA/ 200 DMA
DIFFERENT STROKES FOR DIFFERENT FOLKS
Doktornolittle re:
Holy$#&n Moly!
the peanut gallery refrain: "Can't understand what you're saying .... could you explain!"
CE0 Linda Powers is empoweringly UNDETERRED and having Doc_Logic by one’s side is a Godsend:
Re on Biotech Values board:
ursday, 09/05/19 04:24:46 PM
Re: JohnWayne post# 226096 0
Post # of 226114
NWBO: this guy was an MSL at Merck. That’s tantamount to hiring some random sales rep and appointing them as the Head of Commercial Operations. Not exactly a sign of being able to attract top talent for senior management: re JohnWayne
maverick_1,
Agreed and if Dr. Kevin Duffy has looked deep enough he might have come to the same conclusion I have that NWBO does not need checkpoint inhibitors to join them for the longer term. That would be a real good reason to leave a good paying prestigious job at Merck at this point as a younger player moving into an expanding field of study. Best wishes.
Miltong re:
Re: manibiotech Post# 242718
manibioech, I understand (from posters here as well as form SOS) some can sell fake (naked) shares. But can any body buy fake shares, so that it can't be traced?
CEO Linda Powers spent a fair amount of time in early Feb 2019 at Annual Shareholders Meeting citing:
We have many individual shareholders owning over 10 MILLION shares that have NOT been DELIVERED!
The SOURCE of these Naked Shorts is IRONICALLY our Retail Shareholders!
Marzan re:
flipper was I guess predicting this. BMY failed in gbm PFS, it's official. They got $10B from AMGN. I thought that money would satisfy LP. But she went with MRK apparently
Ned Sharpless in final running for FDA commish with MD Anderson exec and Harvard prof — reports
]The Trump administration is apparently down to three final candidates for the top FDA job as a deadline for nomination looms. Acting commissioner Ned Sharpless is contending with Stephen Hahn, chief of radiation oncology at MD Anderson, and Harvard dermatology professor Alexa Boer Kimball, according to reports.
Stephen Hahn
Conspicuously absent from the group is Brett Giroir, the controversial assistant secretary of HHS who reportedly enjoyed the favor of Alex Azar, his boss at the department. Azar ended up not recommending him to the White House for fear of a difficult Senate confirmation, sources told BioCentury.
First reported by the Wall Street Journal and later confirmed by BioCentury, news about the list broke on the same day former FDA leaders and patient advocacy nonprofits came out with ringing endorsement of Sharpless. Mark McClellan, Andrew von Eschenbach, Robert Califf and Margaret Hamburg signed a letter voicing support for Sharpless — who was director of the National Cancer Institute — as did dozens of groups including Friends of Cancer Research, the National Brain Tumor Society and the Leukemia and Lymphoma Society.
Alexa Kimball
Trump must make a decision about the commissioner of food and drugs by November 1, 210 days after Scott Gottlieb made an abrupt exit in the middle of a widely admired tenure.
Lending credence to the common perception that Sharpless was his chosen successor, Gottlieb offered his own recommendation in a tweet that is “pinned” to the top of his Twitter profile today:
As early as June the WSJ has suggested that Kimball, chief executive of the Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, was in the running alongside an unnamed doctor at MD Anderson. Hahn was not identified until late Wednesday but has emerged as a leading candidate, the paper reported citing people familiar with the matter.
AUTHOR
Amber Tong
ASSOCIATE EDITOR
One of my posts on NVCR's Optune
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150517423
DIFFERENT STROKES FOR DIFFERENT FOLKS
Evaluate re:
Truthfan, I do indeed see various links about Kevin Duffy that inform about the recent appointment, but what I meant is: if I do a google search for "Kevin Duffy" & Merck & Keytruda (for links that existing prior to the NWBO announcement) ... then I do not see much. Since the PR and Linkedin indicate that Kevin Duffy had such an important role/title at Merck, then I would have thought that I would find more info.
Reposted on iHub Biotech Values following an extensive edit:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150953736
DIFFERENT STROKES FOR DIFFERENT FOLKS
NWBO: this guy was an MSL at Merck. That’s tantamount to hiring some random sales rep and appointing them as the Head of Commercial Operations. Not exactly a sign of being able to attract top talent for senior management: re JohnWayne
He WAS a Medical Science Liason (MSL) from 2008-2014!
AND In Dr. Kevin T. Duffy last ~6 yrs:
Merck
Total Duration5 yrs 9 mos
TitleResearch Scientific Director
Dates EmployedMay 2018 – Sep 2019
Employment Duration1 yr 5 mos
LocationWeston, FL
TitleDirector, Scientific Affairs - Hematology Strategy and Training
Dates EmployedJan 2017 – May 2018
Employment Duration1 yr 5 mos
LocationWeston, FL
TitleOncology Scientific Director
Dates EmployedJan 2014 – Jan 2017
Employment Duration3 yrs 1 mo
Dr. Duffy is joining NW Bio from Merck, where he has served as Research Scientific Director in the Keytruda® (pembrolizumab) program during the last five years. Dr. Duffy’s roles included scientific support and outreach to health care providers and national and regional scientific leaders in over 20 different solid tumors and hematologic malignancies (blood cancers and lymphomas) relating to Merck’s clinical development and commercialization of Keytruda, as well as ongoing scientific support for Merck’s Investigator-Initiated Study Program. He served as the national contact point between the scientific affairs team working with medical professionals in the field and the internal research and development team in Merck for the Keynote-024 study in first-line non-small cell lung cancer, the Keynote-522 and -756 studies in triple negative breast cancer and ER+/HER2- breast cancer, and the Keynote-641 study in metastatic prostate cancer.
Dr. Duffy also served as Scientific Affairs Strategy and Training Lead in Merck’s Global Center for Scientific Affairs for Merck’s immuno-oncology franchise for hematologic malignancies. Dr. Duffy was the recipient of numerous achievement awards during his tenure at Merck.
In his roles at Merck, Dr. Duffy has been involved in the Keytruda development program from its early days through its wide commercialization. He has gained extensive experience with clinical trial designs and strategies, clinical results and feedback from medical professionals. He has built a nationwide network with key opinion leaders in both the clinical and the scientific arenas.
Prior to his time at Merck, Dr. Duffy served in Medical Affairs and Scientific Affairs positions in several pharmaceutical companies, including as a Regional Scientific Manager for oncology and cardiovascular therapeutics at AstraZeneca. Dr. Duffy has a Ph.D. in molecular pharmacology and structural biology, with a focus on oncology, as well as an MBA.
Dr. Duffy commented “My years at Merck, from inception of the Keytruda programs, have been exciting and invaluable. As I look forward now to the next wave of advances in immune therapies for cancer, I am excited about the potential of NW Bio’s DCVax technologies to deliver new breakthroughs for patients. I hope to build on my experience in immuno-oncology and my network of relationships in the field to help NW Bio achieve this potential.”
Linda Powers, CEO of NW Bio, noted that “Dr. Duffy’s experience with immune therapies for cancer and one of the most successful product development programs in the field will be an invaluable addition to our team. We at NW Bio could not be more excited about Dr. Duffy’s choice to join us and help realize the broad potential of DCVax.”
Early Ph2 NWBO Program Outreach response on BiotechValues board re NWBO: Dr. Kevin T Duffy :
NWBO: this guy was an MSL at Merck. That’s tantamount to hiring some random sales rep and appointing them as the Head of Commercial Operations. Not exactly a sign of being able to attract top talent for senior management: re JohnWayne
That's your selective BIASED in Semantics & NOT UP to DATE parsing: shades of AdamFeuerstein 's (drinking buddy of DewDiligence)distortionist views: NWBO is ALIVE! From the TWICE ASHES to.... without correlating to NWBO's DCVAX Technology PLATFORM! in INOPERABLE SOLID TUMORS.......
DewDiligence re:
You posted that in reply to a message about NWBO? [Rhetorical
Cancer overtakes heart disease as biggest rich-world killer
SEPTEMBER 3, 2019 / 2:08 AM / 2 DAYS AGO
LONDON (Reuters) -
Cancer has overtaken heart disease as the leading cause of death in wealthy countries and could become the world’s biggest killer within just a few decades if current trends persist, researchers said on Tuesday.
Publishing the findings of two large studies in The Lancet medical journal the scientists said they showed evidence of a new global “epidemiologic transition” between different types of chronic disease.
While cardiovascular disease remains, for now, the leading cause of mortality worldwide among middle-aged adults - accounting for 40% of all deaths - that is no longer the case in high-income countries, where cancer now kills twice as many people as heart disease, the findings showed.
“Our report found cancer to be the second most common cause of death globally in 2017, accounting for 26% of all deaths. But as (heart disease) rates continue to fall, cancer could likely become the leading cause of death worldwide, within just a few decades,” said Gilles Dagenais, a professor at Quebec’s Laval University in Canada who co-led the work.
Of an estimated 55 million deaths in the world in 2017, the researchers said, around 17·7 million were due to cardiovascular disease - a group of conditions that includes heart failure, angina, heart attack and stroke.
Around 70% of all cardiovascular cases and deaths are due to modifiable risks such as high blood pressure, high cholesterol, diet, smoking and other lifestyle factors.
In high-income countries, common treatment with cholesterol-lowering statins and blood-pressure medicines have helped bring rates of heart disease down dramatically in the past few decades.
Dagenais’ team said their findings suggest that the higher rates of heart-disease deaths in low-income countries may be mainly due to a lower quality of healthcare.
The research found first hospitalization rates and heart disease medication use were both substantially lower in poorer and middle-income countries than in wealthy ones.
The research was part of the Prospective Urban and Rural Epidemiologic (PURE) study, published in The Lancet and presented at the ESC Congress in Paris.
Countries analyzed included Argentina, Bangladesh, Brazil, Canada, Chile, China, Colombia, India, Iran, Malaysia, Pakistan, Palestine, Philippines, Poland, Saudi Arabia, South Africa, Sweden, Tanzania, Turkey, United Arab Emirates and Zimbabwe[/quote]
https://www.reuters.com/article/us-health-cancer-cancer/cancer-overtakes-heart-disease-as-biggest-rich-world-killer-idUSKCN1VO0VP
DIFFERENT STROKES FOR DIFFERENT FOLKS
Cancer overtakes heart disease as biggest rich-world killer
SEPTEMBER 3, 2019 / 2:08 AM / 2 DAYS AGO
LONDON (Reuters) -
Cancer has overtaken heart disease as the leading cause of death in wealthy countries and could become the world’s biggest killer within just a few decades if current trends persist, researchers said on Tuesday.
Publishing the findings of two large studies in The Lancet medical journal, the scientists said they showed evidence of a new global “epidemiologic transition” between different types of chronic disease.
While cardiovascular disease remains, for now, the leading cause of mortality worldwide among middle-aged adults - accounting for 40% of all deaths - that is no longer the case in high-income countries, where cancer now kills twice as many people as heart disease, the findings showed.
“Our report found cancer to be the second most common cause of death globally in 2017, accounting for 26% of all deaths. But as (heart disease) rates continue to fall, cancer could likely become the leading cause of death worldwide, within just a few decades,” said Gilles Dagenais, a professor at Quebec’s Laval University in Canada who co-led the work.
Of an estimated 55 million deaths in the world in 2017, the researchers said, around 17·7 million were due to cardiovascular disease - a group of conditions that includes heart failure, angina, heart attack and stroke.
Around 70% of all cardiovascular cases and deaths are due to modifiable risks such as high blood pressure, high cholesterol, diet, smoking and other lifestyle factors.
In high-income countries, common treatment with cholesterol-lowering statins and blood-pressure medicines have helped bring rates of heart disease down dramatically in the past few decades.
Dagenais’ team said their findings suggest that the higher rates of heart-disease deaths in low-income countries may be mainly due to a lower quality of healthcare.
The research found first hospitalization rates and heart disease medication use were both substantially lower in poorer and middle-income countries than in wealthy ones.
The research was part of the Prospective Urban and Rural Epidemiologic (PURE) study, published in The Lancet and presented at the ESC Congress in Paris.
Countries analyzed included Argentina, Bangladesh, Brazil, Canada, Chile, China, Colombia, India, Iran, Malaysia, Pakistan, Palestine, Philippines, Poland, Saudi Arabia, South Africa, Sweden, Tanzania, Turkey, United Arab Emirates and Zimbabwe
Cancer overtakes heart disease as biggest rich-world killer
SEPTEMBER 3, 2019 / 2:08 AM / 2 DAYS AGO
LONDON (Reuters) -
Cancer has overtaken heart disease as the leading cause of death in wealthy countries and could become the world’s biggest killer within just a few decades if current trends persist, researchers said on Tuesday.
Publishing the findings of two large studies in The Lancet medical journal, the scientists said they showed evidence of a new global “epidemiologic transition” between different types of chronic disease.
While cardiovascular disease remains, for now, the leading cause of mortality worldwide among middle-aged adults - accounting for 40% of all deaths - that is no longer the case in high-income countries, where cancer now kills twice as many people as heart disease, the findings showed.
“Our report found cancer to be the second most common cause of death globally in 2017, accounting for 26% of all deaths. But as (heart disease) rates continue to fall, cancer could likely become the leading cause of death worldwide, within just a few decades,” said Gilles Dagenais, a professor at Quebec’s Laval University in Canada who co-led the work.
Of an estimated 55 million deaths in the world in 2017, the researchers said, around 17·7 million were due to cardiovascular disease - a group of conditions that includes heart failure, angina, heart attack and stroke.
Around 70% of all cardiovascular cases and deaths are due to modifiable risks such as high blood pressure, high cholesterol, diet, smoking and other lifestyle factors.
In high-income countries, common treatment with cholesterol-lowering statins and blood-pressure medicines have helped bring rates of heart disease down dramatically in the past few decades.
Dagenais’ team said their findings suggest that the higher rates of heart-disease deaths in low-income countries may be mainly due to a lower quality of healthcare.
The research found first hospitalization rates and heart disease medication use were both substantially lower in poorer and middle-income countries than in wealthy ones.
The research was part of the Prospective Urban and Rural Epidemiologic (PURE) study, published in The Lancet and presented at the ESC Congress in Paris.
Countries analyzed included Argentina, Bangladesh, Brazil, Canada, Chile, China, Colombia, India, Iran, Malaysia, Pakistan, Palestine, Philippines, Poland, Saudi Arabia, South Africa, Sweden, Tanzania, Turkey, United Arab Emirates and Zimbabwe
IMHO FFS negative ST opinion was premature: AFTER today's action this is my take:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150933215
DIFFERENT STROKES FOR DIFFERENT FOLKS
North4000 et al: FWIW Last 2 days Good Positive Action towards KEY $18 to begin to put the finish to "the three interim phase UP consolidation moves since R-IT results late 9/18" :
Todays above avg volume vs the markets LOW volume is another good sign
On a Point & Figure today's action: Double Top BREAKOUT:
https://stockcharts.com/freecharts/gallery.html?Amrn
ALSO AMRN BESTED that of XBI: Emerging Biotech Index Benchmark in these critical categories:
Go to Stockcharts.com and get SharpCharts for:
Then input these in the 2nd & 3rd drop down menu's in case those links don't depict the following:
1) RSI
2) MACD
3)FAST STOC:
4) Better Bollinger Band
5) Better 50 DMA/200DMA
This should be educational in time.
Hopefully those conferences CEO JT are attending brings buying.
DIFFERENT STROKES FOR DIFFERENT FOLKS
BTW: https://investorshub.advfn.com/uimage/uploads/2019/9/4/ptgpfsc-65.png
due to the most strategic of all hires:
https://www.prnewswire.com/news-releases/nw-bio-expands-senior-management-team-with-dr-kevin-duffy-as-vice-president-medical-affairs--external-collaborations-300911423.html
ADVFN_doclee re:
Maverick, I'm sorry that the sentiments I added to your posting were not set out in a clearer way as a result of which you have taken justified umbrage at what you see as an undeserved and unbased slur. For this I apologise to you.
My posting was not meant to be a response to your's but was intended as an addendum aimed at some other contributors to this board who earlier in the year gloated over Woodford's misfortunes and wished him worse. I pointed out to them that the result of their wishes would be even more collateral damage to those invested in Woodford's funds, something which did not seem to cut all that much ice with them.
Your posting quantified the extent of that collateral damage and I felt it would be helpful to emphasise the numbers of investors who are affected by Woodford's failure and whose plight would be worsened if Woodford's funds went further down the pan. I now realise that I should have started off my comment by thanking you (as I do now) for the figures you had provided.
As to your advice given earlier to me about your experience, I did indeed read your postings which provided me with the answer that you were without doubt experienced in investment matters.
Once again, my apologies. doclee
Marzan re:
There is not a single day I forget to thank you for bringing me into this stock maverick. Thank you for ever! What a great stock!!
STARS ARE ALIGNED:
Simpletons who just punt daily viewing this as LACK of VOLUME
TOTALLY IGNORE what has BEEN HAPPENING over the last few MONTHS:
BIGGER Capital despite ALL the unending posts over the LAST YEAR has as I indicated in my first post on Bigger Capital: they DO HAVE the $power of their convictions despite
ALL the NONSENSE from truly myopic posters!
Not only did BIGGER Capital DO TWO private placements
BIGGER took a BIG chunk of Woodforth's position which most all did NOT foresee what unfolded in late 2015! when the shares were $4=$5! Bully pulpited Pied Pipers made it much worse!
Lots of careful accumulation IN STRONGER HANDS NOW will NOT sell based on what is CLEARLY UNFOLDING especially with this MOST STRATEGIC of HIRES!
AND Hot and Cold daily whiners lacking real conviction were saying single digits!
EVEN Reverse Stock Split
GREAT to have questions but not an UNENDING stream of misdirected ones.
Some will never learn but hopefully most will not forget the EPIC SAGA here of years of cathartic pain.
Fortunately I READ the Tea Leaves (especially that of CEO Linda Powers) correctly despite THE YEARS of SILENCE
I have always been a Maverick in any undertaking and do not get swayed by others although Pyrrh and Flipper did early on haD that effect but not after what I've seen since late 2015.
ALWAYS better to have the right answers: to be AHEAD OF THE CURVE versus being a parasite!
DIFFERENT STROKES FOR DIFFERENT FOLKS
Sojourner re:
Afford, if you look at CPXX and AMRN, volume was low prior to results and then exploded on news. Those that are accumulating do it over time without moving the price much. Volume only moves if there is a leak such as impending takeover. Look at KITE and JUNO.
Afford,The only problem as I see it (HE's ALWAYS Pissing and Moaning in a varied misguided stream: same for Manibiotech) is the low volume, and that is a shame. Can't party with such low volume.
Stars ALIGNED
https://nwbio.com/nw-bio-expands-senior-management-team-with-dr-kevin-duffy-as-vice-president-medical-affairs-external-collaborations/
DIFFERENT STROKES FOR DIFFERENT FOLKS
JL: https://nwbio.com/nw-bio-expands-senior-management-team-with-dr-kevin-duffy-as-vice-president-medical-affairs-external-collaborations/
DIFFERENT STROKES FOR DIFFERENT FOLKS
That’s why Sukus & Maverick were ONLY talking about Kobe Steak which is massaged daily with special Kirin beer to produce the unbelievable butter smooth texturize and taste of $NWBO! At $160+ per lb worth the NWBO celebration !
https://www.crowdcow.com/products/japanese-wagyu-ribeye-steak?gclsrc=aw.ds&&utm_source=google&utm_medium=cpcnb&utm_campaign=G_PLA_WC_NB_TopTerms&utm_term=&utm_content=313683720715&gclid=Cj0KCQjwwb3rBRDrARIsALR3XeaYnnYijApv8ULRcIasoSuO4zC2skygBBU6Ui8_VoKNwyay1SRp1pIaAkP2EALw_wcB
And if you can’t go to Tokyo: NYC’s Peter Lugers as certify by Iwasadiver is a superb alternative.
Our quartet of Sukus; Maverick; Iwasadiver and Dr Bala would only recommend and defend
The Best: Northwest Biotherapeutics
My strategic life changing plans 4 years ago of spending the rest of my life in Europe is no longer just in my mind! as I have been executing in nonstop buying over the last 3 years!
Invariably I always get the last laugh at the plethora of snipers I have had to endure along with
hundreds of post deletions:
That’s why it pays to always have the RELEVANT professional experience go The EXTRA MILE with Program OUTREACH for NEW Blood Infusion along with 90 hr weekSSS!
DIFFERENT STROKES FOR DIFFERENT FOLKS
Thanks for the recommendation:
I might attempt that when I make the full transition across the pond.
Love the 150 mile radius around Florence especially the suburbs: Sienna, Pisa; Tuscany countryside is oh la la!; did drive and hiked Cinque Terre which is now mobbed; left out the famous marble quarries.
So even though I have done driven Italy thrice: never enough
Scariest drive is at night by Ravello: Amalfi Coast
DIFFERENT STROKES FOR DIFFERENT FOLKS
TiltMyBrain
It all about the marbling!!!